131 related articles for article (PubMed ID: 17117454)
1. In vitro metabolism of ciclesonide in human nasal epithelial cells.
Sato H; Nave R; Nonaka T; Mochizuki T; Takahama S; Kondo S
Biopharm Drug Dispos; 2007 Jan; 28(1):43-50. PubMed ID: 17117454
[TBL] [Abstract][Full Text] [Related]
2. Uptake and metabolism of ciclesonide and retention of desisobutyryl-ciclesonide for up to 24 hours in rabbit nasal mucosa.
Sato H; Nave R; Nonaka T; Yoshihisa N; Atsuhiro N; Mochizuki T; Takahama S; Kondo S; Wingertzahn M
BMC Pharmacol; 2007 Jun; 7():7. PubMed ID: 17553148
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of ciclesonide in the upper and lower airways: review of available data.
Nave R; McCracken N
J Asthma Allergy; 2008 Sep; 1():11-8. PubMed ID: 21436981
[TBL] [Abstract][Full Text] [Related]
4. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide.
Nave R; Meyer W; Fuhst R; Zech K
Pulm Pharmacol Ther; 2005; 18(6):390-6. PubMed ID: 16179214
[TBL] [Abstract][Full Text] [Related]
5. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue.
Mutch E; Nave R; McCracken N; Zech K; Williams FM
Biochem Pharmacol; 2007 May; 73(10):1657-64. PubMed ID: 17331475
[TBL] [Abstract][Full Text] [Related]
6. Ciclesonide uptake and metabolism in human alveolar type II epithelial cells (A549).
Nonaka T; Nave R; McCracken N; Kawashimo A; Katsuura Y
BMC Pharmacol; 2007 Sep; 7():12. PubMed ID: 17900334
[TBL] [Abstract][Full Text] [Related]
7. Deposition and metabolism of inhaled ciclesonide in the human lung.
Nave R; Watz H; Hoffmann H; Boss H; Magnussen H
Eur Respir J; 2010 Nov; 36(5):1113-9. PubMed ID: 20351025
[TBL] [Abstract][Full Text] [Related]
8. In vitro metabolism of beclomethasone dipropionate, budesonide, ciclesonide, and fluticasone propionate in human lung precision-cut tissue slices.
Nave R; Fisher R; McCracken N
Respir Res; 2007 Sep; 8(1):65. PubMed ID: 17883839
[TBL] [Abstract][Full Text] [Related]
9. In vitro activation of the corticosteroid ciclesonide in animal nasal mucosal homogenates.
Sato H; Nave R; Nonaka T; Mochizuki T; Takahama S; Kondo S
Biopharm Drug Dispos; 2007 Mar; 28(2):59-64. PubMed ID: 17163410
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro metabolism of 14C-ciclesonide in hepatocytes from the mouse, rat, rabbit, dog, and human.
Gu Z; Zhao XG; Nave R; Liu DD; Feng H; Wu J; Howell SR; Guo Z
Am J Ther; 2007; 14(3):280-90. PubMed ID: 17515705
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of ciclesonide and desisobutyryl ciclesonide after administration via aqueous nasal spray or hydrofluoroalkane nasal aerosol compared with orally inhaled ciclesonide: an open-label, single-dose, three-period crossover study in healthy volunteers.
Nave R; Herzog R; Laurent A; Wingertzahn MA
Clin Ther; 2009 Dec; 31(12):2988-99. PubMed ID: 20110036
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma.
Richter K; Kanniess F; Biberger C; Nave R; Magnussen H
J Clin Pharmacol; 2005 Feb; 45(2):146-52. PubMed ID: 15647406
[TBL] [Abstract][Full Text] [Related]
13. An investigation of the pharmacokinetics, pharmacodynamics, safety, and tolerability of ciclesonide hydrofluoroalkane nasal aerosol in healthy subjects and subjects with perennial allergic rhinitis.
Ratner P; Wingertzahn MA; Herzog R; Huang H; Desai SY; Maier G; Nave R
Pulm Pharmacol Ther; 2011 Aug; 24(4):426-33. PubMed ID: 21501692
[TBL] [Abstract][Full Text] [Related]
14. Visualizing the spatial localization of ciclesonide and its metabolites in rat lungs after inhalation of 1-μm aerosol of ciclesonide by desorption electrospray ionization-time of flight mass spectrometry imaging.
Yamamoto E; Taquahashi Y; Kuwagata M; Saito H; Matsushita K; Toyoda T; Sato F; Kitajima S; Ogawa K; Izutsu KI; Saito Y; Hirabayashi Y; Iimura Y; Honma M; Okuda H; Goda Y
Int J Pharm; 2021 Feb; 595():120241. PubMed ID: 33484917
[TBL] [Abstract][Full Text] [Related]
15. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide.
Rohatagi S; Luo Y; Shen L; Guo Z; Schemm C; Huang Y; Chen K; David M; Nave R; King SP
Am J Ther; 2005; 12(3):201-9. PubMed ID: 15891262
[TBL] [Abstract][Full Text] [Related]
16. Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of the AeroChamber Plus spacer for inhalation.
Drollmann A; Nave R; Steinijans VW; Baumgärtner E; Bethke TD
Clin Pharmacokinet; 2006; 45(7):729-36. PubMed ID: 16802853
[TBL] [Abstract][Full Text] [Related]
17. Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl-ciclesonide.
Böhmer GM; Drollmann A; Gleiter CH; Nave R
Clin Pharmacokinet; 2008; 47(5):343-9. PubMed ID: 18399715
[TBL] [Abstract][Full Text] [Related]
18. In Vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices.
Nave R; Fisher R; Zech K
Biopharm Drug Dispos; 2006 May; 27(4):197-207. PubMed ID: 16566061
[TBL] [Abstract][Full Text] [Related]
19. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects.
Nave R; Zech K; Bethke TD
Eur J Clin Pharmacol; 2005 May; 61(3):203-8. PubMed ID: 15824911
[TBL] [Abstract][Full Text] [Related]
20. LC-HRMS/MS study of the prodrug ciclesonide and its active metabolite desisobutyryl-ciclesonide in plasma after an inhalative administration to horses for doping control purposes.
Trevisiol S; Moulard Y; Kaabia Z; Delcourt V; Loup B; Garcia P; Boyer S; Dauriac K; Groseille G; Rouger S; Narbe R; Popot MA; Bailly-Chouriberry L
Drug Test Anal; 2022 Feb; 14(2):252-261. PubMed ID: 34634175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
